Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs"

被引:1
|
作者
Spitaleri, Gianluca [1 ]
Aliaga, Pamela Trillo [1 ]
Attili, Ilaria [1 ]
Del Signore, Ester [1 ]
Corvaja, Carla [1 ]
Pellizzari, Gloria [2 ,3 ]
Katrini, Jalissa [2 ,3 ]
Passaro, Antonio [1 ]
de Marinis, Filippo [1 ]
机构
[1] IRCCS, European Inst Oncol IEO, Div Thorac Oncol, Via Ripamonti 435, I-20141 Milan, Italy
[2] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, I-20141 Milan, Italy
[3] Univ Milan, Dept Oncol & Haematol DIPO, I-20122 Milan, Italy
关键词
NSCLC; RET; RET gene fusion; RET multi-targeted inhibitors; new selective RET inhibitors; pralsetinib; selpercatinib; toxicity; resistance mechanism; new drugs; TYROSINE KINASE INHIBITOR; DEMONSTRATES ROBUST ACTIVITY; PHASE I/II ARROW; OPEN-LABEL; ACQUIRED-RESISTANCE; PATIENTS PTS; SINGLE-ARM; NEUROTROPHIC FACTOR; HIGHLY POTENT; TARGETING RET;
D O I
10.3390/cancers16162877
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary RET fusions are relatively rare in Non-Small-Cell Lung Cancers (NSCLCs), being around 1-2% of all NSCLCs. Chemotherapy and immunotherapy have a low impact on the prognosis of patients with RET fusions positive NSCLC. Multitargeted RET inhibitors have shown modest activity jeopardized by high toxicity. New potent and selective RET inhibitors (RET-Is) (pralsetinib and selpercatinib) have achieved a higher efficacy in minimizing the known toxicities of the old drugs. This review will focus on the advent of new potent and selective RET-Is. We will describe their efficacy as well as the main mechanisms of resistance to them. We will further proceed to deal with new drugs and strategies proposed to overcome the resistance to RET-Is. In the last section, we will also focus on the safety profile of RET-Is, dealing with the main toxicities as well as the rare but severe adverse events.Abstract RET fusions are relatively rare in Non-Small-Cell Lung Cancers (NSCLCs), being around 1-2% of all NSCLCs. They share the same clinical features as the other fusion-driven NSCLC patients, as follows: younger age, adenocarcinoma histology, low exposure to tobacco, and high risk of spreading to the brain. Chemotherapy and immunotherapy have a low impact on the prognosis of these patients. Multitargeted RET inhibitors have shown modest activity jeopardized by high toxicity. New potent and selective RET inhibitors (RET-Is) (pralsetinib and selpercatinib) have achieved a higher efficacy minimizing the known toxicities of the multitargeted agents. This review will describe the sensitivity of immune-checkpoint inhibitors (ICIs) in RET fusion + NSCLC patients, as well their experiences with the 'old' multi-targeted RET inhibitors. This review will focus on the advent of new potent and selective RET-Is. We will describe their efficacy as well as the main mechanisms of resistance to them. We will further proceed to deal with the new drugs and strategies proposed to overcome the resistance to RET-Is. In the last section, we will also focus on the safety profile of RET-Is, dealing with the main toxicities as well as the rare but severe adverse events.
引用
收藏
页数:29
相关论文
共 50 条
  • [41] Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
    Subbiah, Vivek
    Gainor, Justin F.
    Oxnard, Geoffrey R.
    Tan, Daniel S. W.
    Owen, Dwight H.
    Cho, Byoung Chul
    Loong, Herbert H.
    Mccoach, Caroline E.
    Weiss, Jared
    Kim, Yu Jung
    Bazhenova, Lyudmila
    Park, Keunchil
    Daga, Haruko
    Besse, Benjamin
    Gautschi, Oliver
    Rolfo, Christian
    Zhu, Edward Y.
    Kherani, Jennifer F.
    Huang, Xin
    Kang, Suhyun
    Drilon, Alexander
    CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4160 - 4167
  • [42] Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
    Sousa, D.
    Afonso, M.
    Rocha, D.
    Craveiro, A.
    Martins, S.
    Barata, J.
    Valente, M. L. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S413 - S414
  • [43] Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion plus non-small-cell lung cancer (NSCLC).
    Drilon, Alexander E.
    Gautschi, Oliver
    Besse, Benjamin
    Subbiah, Vivek
    Tan, Daniel Shao-Weng
    Park, Keunchil
    De Braud, Filippo G.
    Alonso, Guzman
    Wolf, Juergen
    Soldatenkova, Victoria
    French, Pearl Plernjit
    Lin, Aimee K.
    Goto, Koichi
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers
    Kodama, Tatsushi
    Tsukaguchi, Toshiyuki
    Satoh, Yasuko
    Yoshida, Miyuki
    Watanabe, Yoshiaki
    Kondoh, Osamu
    Sakamoto, Hiroshi
    CANCER RESEARCH, 2015, 75
  • [45] TREATMENT PATTERNS AND OUTCOMES OF RET FUSIONPOSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH SELPERCATINIB IN EUROPE: INTERIM RESULTS FROM THE SPRINT-RET STUDY
    Popat, S.
    Hochmair, M.
    Gastaldo, Sanchez A.
    Hashemi, S.
    Puri, T.
    Khanal, M.
    Pedros, M.
    Cuadras, D.
    Segall, G.
    VALUE IN HEALTH, 2024, 27 (12) : S582 - S582
  • [46] Safety of alectinib in non-small cell lung cancer patients with RET fusion gene (ALL-RET): Results from the dose-finding portion of a phase 1/2 study
    Nosaki, K.
    Takeuchi, S.
    Takahara, S.
    Kawakami, T.
    Yoh, K.
    Kono, Y.
    Horiike, A.
    Seto, T.
    Goto, K.
    Yoshimura, K.
    Imai, Y.
    Murayama, T.
    Yano, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Genetic profiling and the response to RET inhibitors in RET fusion positive non-small cell lung cancer (NSCLC) identified by international genomic screening project (LC-SCRUM-Asia).
    Nosaki, Kaname
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Ikeda, Takaya
    Ohe, Yuichiro
    Kodani, Masahiro
    Yanagitani, Noriko
    Nishino, Kazumi
    Shingyoji, Masato
    Takeuchi, Shinji
    Zenke, Yoshitaka
    Udagawa, Hibiki
    Kirita, Keisuke
    Niho, Seiji
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
    Illini, Oliver
    Hochmair, Maximilian Johannes
    Fabikan, Hannah
    Weinlinger, Christoph
    Tufman, Amanda
    Swalduz, Aurelie
    Lamberg, Kristina
    Hashemi, Sayed M. S.
    Huemer, Florian
    Vikstrom, Anders
    Wermke, Martin
    Absenger, Gudrun
    Addeo, Alfredo
    Banerji, Shantanu
    Calles, Antonio
    Clarke, Stephen
    Di Maio, Massimo
    Durand, Alice
    Duruisseaux, Michael
    Itchins, Malinda
    Kaaranien, Okko-Sakari
    Krenn, Florian
    Laack, Eckart
    de Langen, Adrianus Johannes
    Mohorcic, Katja
    Pall, Georg
    Passaro, Antonio
    Prager, Gerald
    Rittmeyer, Achim
    Rothenstein, Jeffrey
    Schumacher, Michael
    Woell, Ewald
    Valipour, Arschang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [49] RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
    Chunyue Wang
    Zhenlong Zhang
    Yulan Sun
    Song Wang
    Mengmeng Wu
    Qiuxiang Ou
    Yang Xu
    Zhiming Chen
    Yang Shao
    Hong Liu
    Peifeng Hou
    Journal of Translational Medicine, 20
  • [50] RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
    Wang, Chunyue
    Zhang, Zhenlong
    Sun, Yulan
    Wang, Song
    Wu, Mengmeng
    Ou, Qiuxiang
    Xu, Yang
    Chen, Zhiming
    Shao, Yang
    Liu, Hong
    Hou, Peifeng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)